Can Neupogen Cause Fever?
Yes, Neupogen (filgrastim) can cause fever as a side effect, though it is generally mild (grade 1-2) and occurs less frequently than with GM-CSF products.
Evidence of Fever as a Side Effect
The available evidence demonstrates that fever can occur with filgrastim use, though the incidence and severity vary:
Comparative studies show that less frequent dosing schedules of G-CSF (filgrastim) demonstrated less grade 1 to 2 fever compared to daily administration, suggesting that fever is a recognized adverse effect that may be dose-schedule dependent 1.
When comparing G-CSF (filgrastim) to GM-CSF, systematic reviews concluded that GM-CSF arms demonstrated a higher incidence of fever, indicating that while filgrastim can cause fever, it does so less frequently than alternative colony-stimulating factors 1.
Clinical Context and Differentiation
It is critical to distinguish between fever caused by filgrastim itself versus fever from underlying infection:
Fever occurring with filgrastim therapy in the context of rising neutrophil counts and improving clinical status represents a benign drug effect, whereas fever with neutropenia and clinical deterioration suggests infection requiring immediate evaluation 2.
If fever ≥38.0°C develops during filgrastim therapy, blood and urine cultures should be obtained and broad-spectrum antibiotics initiated immediately, as recommended by infectious disease guidelines, since the primary concern is always ruling out infection in neutropenic patients 2.
Incidence and Severity
The fever associated with filgrastim is typically mild:
Clinical trials documented grade 1 to 2 fever (mild to moderate) as the primary fever-related adverse effect, with more severe febrile complications being rare and typically related to underlying neutropenia rather than the drug itself 1.
In observational studies of filgrastim use in community practice, the overall incidence of febrile neutropenia was 6.5%, though this represents fever with neutropenia (a complication filgrastim is meant to prevent) rather than drug-induced fever alone 3.
Clinical Management Approach
When fever occurs in a patient receiving filgrastim:
Assess the clinical context: Check the neutrophil count trend and overall clinical status 2.
If neutrophils are rising and the patient appears well, the fever is likely a benign drug effect and filgrastim can be continued 2.
If fever occurs with neutropenia (ANC <0.5 × 10⁹/L) or signs of clinical deterioration, immediately evaluate for infection with cultures and initiate empiric antibiotics 2, 4.
Consider that fever may also represent the underlying condition (febrile neutropenia from chemotherapy) that filgrastim is being used to treat, rather than a drug side effect 4, 5.
Important Caveats
The primary purpose of filgrastim is to reduce the incidence and duration of febrile neutropenia, so any fever in a neutropenic patient should be presumed infectious until proven otherwise, regardless of filgrastim use 4, 5, 6.
Fever is not listed among the major serious adverse effects requiring immediate discontinuation in FDA labeling, which focuses instead on splenic rupture, acute respiratory distress syndrome, serious allergic reactions, and other severe complications 7.
Mild fever without other concerning features does not require discontinuation of filgrastim therapy, as the benefits of neutrophil recovery typically outweigh this minor adverse effect 1.